top of page
FAQ
Reach out to us if you need help with these topics
mRNA
DNA and Protein
Automation
CDMO & Supply Chain Management
CMC
General
How can we reduce mRNA royalty and licensing costs and avoid common pitfalls?
How can we reduce COGS during late-stage mRNA development?
How can we reduce COGS during the IVT reaction?
What are the design workaround strategies for mRNA IP?
How do you go about designing mRNA sequences for tissue-specific expression?
How do you classify starting material v/s critical raw material for mRNA?
Do all components of the IVT reaction need to be fully GMP sourced?
How do you quantify dsRNA and what critical analytics are needed for mRNA being phase appropriate to the stage of development?
How do you establish a lab from scratch for manufacturing and analytics?
How do you balance in vivo expression v/s stability for maximizing mRNA drug substance potency?
bottom of page